During the past decade, Virginia Urology conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 13 clinical trials were completed, i.e. on average, 54.2% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 6 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Virginia Urology" #1 sponsor was "Ferring Pharmaceuticals" with 6 trials, followed by "Allergan" with 5 trials sponsored, "Abbott" with 2 trials sponsored, "Allena Pharmaceuticals" with 2 trials sponsored and "Dendreon" with 2 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Virginia Urology" #1 collaborator was "Astellas Pharma Inc" with 1 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 1 trials as a collaborator, "NAMSA" with 1 trials as a collaborator, "National Cancer Institute (NCI)" with 1 trials as a collaborator and "PRA Health Sciences" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Virginia Urology" are "Prostate Cancer" (10 trials), "Bladder Cancer" (6 trials), "Prostatic Neoplasms" (4 trials), "Urinary Bladder, Overactive" (3 trials) and "Urinary Incontinence" (3 trials). Many other conditions were trialed in "Virginia Urology" in a lesser frequency.

Most popular intervention types in "Virginia Urology" are "Drug" (27 trials), "Biological" (9 trials), "Device" (7 trials), "Other" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Degarelix" (4 trials), "onabotulinumtoxinA" (3 trials), "Apalutamide" (2 trials) and "Atrasentan" (2 trials). Other intervention names were less common.

The vast majority of trials in "Virginia Urology" are 22 trials for "Male" genders, 21 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Virginia Urology". undefined are not yet recruiting, 4 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Virginia Urology, 1 suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Virginia Urology, 1 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 5 trials that are defined as “Not Applicable".